Inventage Lab

Inventage Lab EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Inventage Lab (389470.KQ) as of Nov 1, 2026 is -65.57 %. In the previous year, Year-over-Year EBITDA Growth was 35.42 % — a change of -285.11% (lower).

EBITDA Growth YoY

-65.57 %

YoY

-285.11%

Last updated:

Year-over-Year EBITDA Growth of Inventage Lab is 2025 -65.57 % . Year-over-Year EBITDA Growth of Inventage Lab was 2024 35.42 % . It decreases by -285.11% lower compared to the previous year.

The Inventage Lab EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2020
-19.44 KRW
Jan 1, 2021
-79.16 KRW
Jan 1, 2022
-14.20 KRW
Jan 1, 2023
-154.00 KRW
Jan 1, 2024
35.42 KRW
Jan 1, 2025
-65.57 KRW
The Inventage Lab EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-65.57 %-285.11%
35.42 %-123.00%
-154.00 %+984.58%
-14.20 %-82.06%
-79.16 %+307.30%
-19.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventage Lab Stock analysis

What does Inventage Lab do? Inventage Lab, Inc. generates revenue through the research, manufacture, and sale of human medicines targeting male pattern baldness, dementia, and prostate cancer, as well as veterinary medicines including combination drugs and chemical castration agents. The company leverages its proprietary platforms for long-acting injections and genetic material drug delivery to develop and scale production of these products. Its human medicine segment focuses on therapeutic areas with significant market demand, while veterinary medicines serve agricultural and companion animal markets. The firm's business model centers on proprietary technology platforms applied to both human and veterinary pharmaceutical development. These platforms enable the company to create and mass-produce innovative drug delivery systems, which are critical for the efficacy of their medicine portfolios. Revenue streams are derived from direct sales of these medicines to healthcare providers and veterinary institutions within their target markets. Inventage Lab, Inc. operates with a dual focus on human and veterinary pharmaceuticals, utilizing its specialized platforms to address unmet medical needs in both sectors. The company's product range includes treatments for specific conditions like male pattern baldness and prostate cancer, alongside veterinary applications such as chemical castration agents, which are sold to relevant industry stakeholders in their respective markets. Inventage Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventage Lab stock

Year-over-Year EBITDA Growth of Inventage Lab is -65.57 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Inventage Lab since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Inventage Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Inventage Lab

All Key Metrics — Inventage Lab